Pharming Group N.V. P/E Ratio

Pharming Group N.V. (PHAR) currently reports a P/E ratio of 75.49. That is above the Healthcare sector average of 26.36. Use the charts on this page to explore Pharming Group N.V.'s P/E ratio history and peer comparisons.

Pharming Group N.V.'s P/E ratio of 75.49 is higher than the Healthcare sector average of 26.36. That is roughly 186.4% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

The P/E ratio is a valuation multiple that relates Pharming Group N.V.'s market price to a fundamental measure such as earnings, sales, or book value. At 75.49, PHAR can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.

Start with the current P/E ratio of 75.49, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 26.36. From there, open related valuation or income-statement pages for Pharming Group N.V., and consider following PHAR for alerts when major investors trade the stock.

Pharming Group N.V. is classified in the Healthcare sector. On P/E ratio, it currently shows 75.49 versus a sector average near 26.36. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing PHAR with unrelated industries.